

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (HI-140) SERCLUTAMAB
 PRONUNCIATION ser kloo' ta mab
 THERAPEUTIC CLAIM Treatment of advanced solid tumors

CHEMICAL NAMES

1. Immunoglobulin G1[238-cysteine], anti-(human epidermal growth factor receptor) (human-*Mus musculus* monoclonal ABT-806 AM1 S238C γ 1-chain), disulfide with human-*Mus musculus* monoclonal ABT-806 AM1 S238C κ -chain, dimer
2. Immunoglobulin G1-kappa, anti-(*Homo sapiens* Epidermal growth factor receptor (Receptor tyrosine-protein kinase erbB-1, EC=2.7.10.1)); monoclonal antibody; γ 1 heavy chain (1-446) [VH (*Homo sapiens* IGHV4-30-4*01 (81%) – (IGHD)-IGHJ4*01 (93%)) [9.7.9] (1-116) -*Homo sapiens* IGHG1*03 {CH1[R⁹⁷>K(213)], CH2[S⁹>C(238)]} (117-446)], (219-214')-disulfide with κ light chain (1'-214') [V-KAPPA (*Mus musculus* IGKV14-100*01 (86%) – IGKJ1*01/*Homo sapiens* IGKV1-12*01 (75%) –IGKJ4*01 (91%))[6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')], dimer (225-225":228-228")-bisdisulfide

STRUCTURAL FORMULA

Heavy chain					
EVQLQESGPG	LVKPSQTL ^{SL}	TCTVSGYSIS	RDFAWN ^{WIR} Q	PPGKLEW ^{MG}	50
YISYNGNTRY	QP ^{SLK} SRITI	SRDT ^{SKN} QFF	LKLNSV ^{TAAD}	TATY ^{YCV} TAS	100
RGFPYWGQGT	LVT ^{VSS} ASTK	GPSV ^{FPL} APS	SKST ^{SGG} TAA	LGCL ^{VKD} YFP	150
EPVTVSWNSG	ALT ^{SGV} HTFP	AVLQ ^{SSG} LYS	LSSV ^{TV} PSS	SLGT ^{QTY} ICN	200
VNHKPSNTKV	DKK ^V EPKSCD	KTH ^{TC} PPCPA	PELL ^{GGP} CVF	LFPP ^{KPK} DTL	250
MISRTPEVTC	VVVD ^V SHEDP	EVK ^{FNW} YVDG	VEV ^{HNA} KTKP	REE ^{QYN} STYR	300
VVSVLTVLHQ	DWL ^{NG} KEYKC	KVSN ^{KAL} PAP	IEKT ^I SKAKG	QPRE ^{PQV} YTL	350
PPSREEMTKN	QVSL ^{TCL} VKVG	FYP ^S DI ^{AVE} W	ESNG ^Q PENNY	KTTP ^{PVL} DSD	400
GSFFLYSKLT	VDK ^{SRW} QQGN	VFSC ^S VMHEA	LHN ^{HYT} QKSL	SLSP ^{GK}	446

Light chain					
DIQMTQSPSS	MSV ^{SVG} DRVT	ITCH ^{SSQ} DIN	SNIG ^{WLQ} QKP	GKSF ^{KGL} IYH	50'
GTNLD ^D GVPS	RFSG ^{SGS} GTD	YTLT ^I SSLQP	EDFAT ^Y CVQ	YAQ ^F PWTFGG	100'
GTKLEIKRTV	AAPS ^V IFPP	SDEQL ^K SGTA	SVV ^{CL} LNNFY	PREAK ^V QWKV	150'
DNALQ ^S NSQ	ESV ^{TE} QDSKD	STYSL ^S STLT	LSKAD ^Y EKHK	VYACE ^V THQG	200'
LSSPV ^T KSFN	RGEC				214'

Disulfide bridges location							
22-96	22"-96"	23'-88'	23"-88"	134'-194'	134"-194"	143-199	143"-199"
214'-219	214"-219"	225-225"	228-228"	260-320	260"-320"	366-424	366"-424"

Glycosylation sites (N)
 Asn-296 Asn-296"

MOLECULAR FORMULA C₆₄₃₈H₉₉₆₄N₁₇₁₀O₂₀₀₅S₄₆ (peptide only)

MOLECULAR WEIGHT 144.8 kDa (peptide only)

TRADEMARK None as yet

SPONSOR	AbbVie
CODE DESIGNATIONS	ABBV-321, PR1594407
<u>CAS</u> REGISTRY NUMBER	2140172-41-2
UNII	RY62FD82YX
WHO NUMBER	10960

gbk